BRPI0719693A2 - Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol - Google Patents

Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol

Info

Publication number
BRPI0719693A2
BRPI0719693A2 BRPI0719693-8A2A BRPI0719693A BRPI0719693A2 BR PI0719693 A2 BRPI0719693 A2 BR PI0719693A2 BR PI0719693 A BRPI0719693 A BR PI0719693A BR PI0719693 A2 BRPI0719693 A2 BR PI0719693A2
Authority
BR
Brazil
Prior art keywords
alpha
beta
quinolinaethanol
demethylamine
naphthalenyl
Prior art date
Application number
BRPI0719693-8A2A
Other languages
English (en)
Inventor
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Remoortere Peter Jozef Maria Van
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0719693(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0719693A2 publication Critical patent/BRPI0719693A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
BRPI0719693-8A2A 2006-12-05 2007-12-03 Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol BRPI0719693A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
BRPI0719693A2 true BRPI0719693A2 (pt) 2013-12-24

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719693-8A2A BRPI0719693A2 (pt) 2006-12-05 2007-12-03 Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol

Country Status (34)

Country Link
US (1) US8546428B2 (pt)
EP (1) EP2086940B1 (pt)
JP (2) JP2010511663A (pt)
KR (1) KR101514700B1 (pt)
CN (2) CN105012303A (pt)
AP (1) AP2498A (pt)
AR (1) AR064149A1 (pt)
AU (1) AU2007328945B2 (pt)
BR (1) BRPI0719693A2 (pt)
CA (1) CA2668512C (pt)
CL (1) CL2007003472A1 (pt)
CY (1) CY1113594T1 (pt)
DK (1) DK2086940T3 (pt)
EA (1) EA017091B9 (pt)
ES (1) ES2387923T3 (pt)
HK (1) HK1214513A1 (pt)
HR (1) HRP20120639T1 (pt)
IL (1) IL199077A (pt)
JO (1) JO2973B1 (pt)
ME (1) ME01456B (pt)
MX (1) MX2009005909A (pt)
MY (1) MY148844A (pt)
NO (1) NO342773B1 (pt)
NZ (1) NZ576485A (pt)
PE (1) PE20081350A1 (pt)
PL (1) PL2086940T3 (pt)
PT (1) PT2086940E (pt)
RS (1) RS52408B (pt)
SI (1) SI2086940T1 (pt)
TW (1) TWI417098B (pt)
UA (1) UA97813C2 (pt)
UY (1) UY30762A1 (pt)
WO (1) WO2008068231A1 (pt)
ZA (1) ZA200903907B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
RS64308B1 (sr) * 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Disperzibilni sastavi
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
TWI712598B (zh) * 2016-07-20 2020-12-11 瑞士商諾華公司 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
US20220062319A1 (en) 2019-01-09 2022-03-03 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
JP2001503411A (ja) 1996-10-28 2001-03-13 ディパートメント オブ ジ アーミー，ユー．エス．ガバメント 抗生物質耐性感染症の処置のための化合物、組成物および方法
CZ341297A3 (cs) * 1996-10-30 1998-05-13 Eli Lilly And Company Způsob zlepšení léčby nebo profylaxe rakoviny prsu
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
MXPA06013888A (es) * 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
EP1789139B1 (en) * 2004-09-02 2012-03-21 Janssen Pharmaceutica NV Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置

Also Published As

Publication number Publication date
US20100028428A1 (en) 2010-02-04
UA97813C2 (uk) 2012-03-26
EA017091B1 (ru) 2012-09-28
KR101514700B1 (ko) 2015-04-24
KR20090087020A (ko) 2009-08-14
CN101547904A (zh) 2009-09-30
JP2015028049A (ja) 2015-02-12
EA200970532A1 (ru) 2009-10-30
AP2498A (en) 2012-10-19
HK1214513A1 (zh) 2016-07-29
NZ576485A (en) 2012-01-12
EP2086940A1 (en) 2009-08-12
WO2008068231A1 (en) 2008-06-12
UY30762A1 (es) 2008-07-03
AR064149A1 (es) 2009-03-18
SI2086940T1 (sl) 2012-09-28
PL2086940T3 (pl) 2012-10-31
AU2007328945B2 (en) 2014-04-03
AP2009004870A0 (en) 2009-06-30
DK2086940T3 (da) 2012-08-20
CA2668512A1 (en) 2008-06-12
JP2010511663A (ja) 2010-04-15
CN105012303A (zh) 2015-11-04
MX2009005909A (es) 2009-06-16
US8546428B2 (en) 2013-10-01
CY1113594T1 (el) 2016-06-22
JO2973B1 (en) 2016-03-15
HRP20120639T1 (hr) 2012-08-31
ME01456B (me) 2014-04-20
CL2007003472A1 (es) 2008-08-22
AU2007328945A1 (en) 2008-06-12
PE20081350A1 (es) 2008-09-18
ZA200903907B (en) 2013-08-28
EP2086940B1 (en) 2012-05-16
EA017091B9 (ru) 2014-10-30
RS52408B (en) 2013-02-28
CA2668512C (en) 2015-03-24
TW200838527A (en) 2008-10-01
PT2086940E (pt) 2012-08-09
JP5894239B2 (ja) 2016-03-23
ES2387923T3 (es) 2012-10-04
MY148844A (en) 2013-06-14
IL199077A (en) 2016-09-29
TWI417098B (zh) 2013-12-01
NO20092535L (no) 2009-08-06
NO342773B1 (no) 2018-08-06

Similar Documents

Publication Publication Date Title
BRPI0719693A2 (pt) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol
BRPI0813908A2 (pt) Seringa com mecanismo de desativar
BRPI0815717A2 (pt) Compostos de imidazopirazina.
BRPI0908874A2 (pt) mecanismo de posicionamento de um leito
DK2449883T3 (da) Herbicidsammensætninger
DK200801228A (da) Fiskefoder
BRPI0716855A2 (pt) barril
CR10353A (es) Nuevos compuestos.
BRPI0813245A2 (pt) Escova de dentes.
BRPI0807004A2 (pt) Sal
DK1998622T3 (da) Herbicidsammensætning
CR10675A (es) Analogos de 2-fenoxipirimidinona
ITGE20050091A1 (it) Incubatrice
DE602007012490D1 (de) Herbizidzusammensetzung
CR10745A (es) Analogos de pirazol
DE502006005852D1 (de) Anleger
BRPI1016163A2 (pt) "unidade lâmina-suporte de lâmina.
BRPI0818848A2 (pt) Compostos de 2,3-di-idro-benzofurano
LU91233B1 (de) Laderaumsystem
BRPI0811781A2 (pt) Compostos de ((fenil) imidazolil)metilquinolinila terapêuticos.
BRPI0820409A2 (pt) Composto de polipeptídeo
ES1064378Y (es) Pieza de ventilacion perfeccionada
ES1063037Y (es) Sarten perfeccionada
FI6749U1 (fi) Vetouistin
ITPE20060008U1 (it) Disuasivo per animali

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]